ZielBio

About:

ZielBio is an early-stage biotechnology company that identifies novel high value disease targets.

Top Investors: Morningside Venture Investments, Mass General Brigham Ventures, Partners Innovation Fund

Description:

ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind. ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States.

Total Funding Amount:

$33M

Headquarters Location:

Charlottesville, Virginia, United States

Founded Date:

2011-01-01

Founders:

Kimberly A. Kelly

Number of Employees:

11-50

Last Funding Date:

2022-09-27

IPO Status:

Private

Industries: